JPWO2020086665A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020086665A5 JPWO2020086665A5 JP2021523230A JP2021523230A JPWO2020086665A5 JP WO2020086665 A5 JPWO2020086665 A5 JP WO2020086665A5 JP 2021523230 A JP2021523230 A JP 2021523230A JP 2021523230 A JP2021523230 A JP 2021523230A JP WO2020086665 A5 JPWO2020086665 A5 JP WO2020086665A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- sequence
- epcam
- antibody fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004965 antibodies Human genes 0.000 claims 180
- 108090001123 antibodies Proteins 0.000 claims 180
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 70
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 70
- 108010027440 Immunoconjugates Proteins 0.000 claims 21
- 102000018748 Immunoconjugates Human genes 0.000 claims 21
- 210000004027 cells Anatomy 0.000 claims 21
- 230000000873 masking Effects 0.000 claims 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims 12
- 201000011510 cancer Diseases 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 239000011780 sodium chloride Substances 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 108010047814 Antigen-Antibody Complex Proteins 0.000 claims 6
- 239000000427 antigen Substances 0.000 claims 6
- 102000038129 antigens Human genes 0.000 claims 6
- 108091007172 antigens Proteins 0.000 claims 6
- 206010017758 Gastric cancer Diseases 0.000 claims 5
- 229920000023 polynucleotide Polymers 0.000 claims 5
- 239000002157 polynucleotide Substances 0.000 claims 5
- 201000011549 stomach cancer Diseases 0.000 claims 5
- 201000011231 colorectal cancer Diseases 0.000 claims 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- 102000033147 ERVK-25 Human genes 0.000 claims 3
- 108091005771 Peptidases Proteins 0.000 claims 3
- 239000004365 Protease Substances 0.000 claims 3
- 206010046766 Uterine cancer Diseases 0.000 claims 3
- -1 Val-Cit Proteins 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 239000000758 substrate Substances 0.000 claims 3
- PVGATNRYUYNBHO-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(2,5-dioxopyrrol-1-yl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O PVGATNRYUYNBHO-UHFFFAOYSA-N 0.000 claims 2
- LCZVQHWMSQLWSC-UHFFFAOYSA-N 1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O LCZVQHWMSQLWSC-UHFFFAOYSA-N 0.000 claims 2
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- DEFJQIDDEAULHB-QWWZWVQMSA-N D-alanyl-D-alanine zwitterion Chemical compound C[C@@H]([NH3+])C(=O)N[C@H](C)C([O-])=O DEFJQIDDEAULHB-QWWZWVQMSA-N 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 claims 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 2
- 206010027476 Metastasis Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038038 Rectal cancer Diseases 0.000 claims 2
- 108010056243 alanylalanine Proteins 0.000 claims 2
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 claims 2
- 201000005202 lung cancer Diseases 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 201000001275 rectum cancer Diseases 0.000 claims 2
- FAQVCWVVIYYWRR-WHFBIAKZSA-N (2S)-2-[[(2S)-2,5-diamino-5-oxopentanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O FAQVCWVVIYYWRR-WHFBIAKZSA-N 0.000 claims 1
- QXRNAOYBCYVZCD-BQBZGAKWSA-N (2S)-6-amino-2-[[(2S)-2-aminopropanoyl]amino]hexanoic acid Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN QXRNAOYBCYVZCD-BQBZGAKWSA-N 0.000 claims 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- NCPQROHLJFARLL-UHFFFAOYSA-N 4-(2,5-dioxopyrrol-1-yl)butanoic acid Chemical compound OC(=O)CCCN1C(=O)C=CC1=O NCPQROHLJFARLL-UHFFFAOYSA-N 0.000 claims 1
- FSHURBQASBLAPO-WDSKDSINSA-N Ala-Met Chemical compound CSCC[C@@H](C(O)=O)NC(=O)[C@H](C)N FSHURBQASBLAPO-WDSKDSINSA-N 0.000 claims 1
- OMLWNBVRVJYMBQ-YUMQZZPRSA-N Arg-Arg Chemical compound NC(N)=NCCC[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O OMLWNBVRVJYMBQ-YUMQZZPRSA-N 0.000 claims 1
- DAQIJMOLTMGJLO-YUMQZZPRSA-N Arg-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H](N)CCCNC(N)=N DAQIJMOLTMGJLO-YUMQZZPRSA-N 0.000 claims 1
- SJUXYGVRSGTPMC-UHFFFAOYSA-N Asparaginyl-Alanine Chemical compound OC(=O)C(C)NC(=O)C(N)CC(N)=O SJUXYGVRSGTPMC-UHFFFAOYSA-N 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 101700038562 CCND1 Proteins 0.000 claims 1
- HHNFORCFJOVQNF-UHFFFAOYSA-N Cyl-1 Chemical compound N1C(=O)C(CCCCCC(=O)C2OC2)NC(=O)C2CCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(OC)C=C1 HHNFORCFJOVQNF-UHFFFAOYSA-N 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- VHLZDSUANXBJHW-UHFFFAOYSA-N Glutaminyl-Phenylalanine Chemical compound NC(=O)CCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 VHLZDSUANXBJHW-UHFFFAOYSA-N 0.000 claims 1
- MRVYVEQPNDSWLH-UHFFFAOYSA-N Glutaminyl-Valine Chemical compound CC(C)C(C(O)=O)NC(=O)C(N)CCC(N)=O MRVYVEQPNDSWLH-UHFFFAOYSA-N 0.000 claims 1
- 108010009504 Gly-Phe-Leu-Gly Proteins 0.000 claims 1
- 125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 claims 1
- 241000282567 Macaca fascicularis Species 0.000 claims 1
- JHKXZYLNVJRAAJ-WDSKDSINSA-N Met-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](C)C(O)=O JHKXZYLNVJRAAJ-WDSKDSINSA-N 0.000 claims 1
- 210000000441 Neoplastic Stem Cells Anatomy 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- MIDZLCFIAINOQN-WPRPVWTQSA-N Phe-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H](N)CC1=CC=CC=C1 MIDZLCFIAINOQN-WPRPVWTQSA-N 0.000 claims 1
- FADYJNXDPBKVCA-UHFFFAOYSA-N Phenylalanyl-Lysine Chemical compound NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 claims 1
- 102000005632 Single-Chain Antibodies Human genes 0.000 claims 1
- 108010070144 Single-Chain Antibodies Proteins 0.000 claims 1
- 206010054184 Small intestine carcinoma Diseases 0.000 claims 1
- 206010044285 Tracheal cancer Diseases 0.000 claims 1
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims 1
- HSRXSKHRSXRCFC-WDSKDSINSA-N Val-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C)C(O)=O HSRXSKHRSXRCFC-WDSKDSINSA-N 0.000 claims 1
- IBIDRSSEHFLGSD-YUMQZZPRSA-N Val-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N IBIDRSSEHFLGSD-YUMQZZPRSA-N 0.000 claims 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 claims 1
- 108010054982 alanyl-leucyl-alanyl-leucine Proteins 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 108010068380 arginylarginine Proteins 0.000 claims 1
- 108010036533 arginylvaline Proteins 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000004113 cell culture Methods 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 150000002019 disulfides Chemical class 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 239000012216 imaging agent Substances 0.000 claims 1
- 150000002500 ions Chemical class 0.000 claims 1
- 108010054155 lysyllysine Proteins 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 108010024607 phenylalanylalanine Proteins 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 108010073969 valyllysine Proteins 0.000 claims 1
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862751530P | 2018-10-26 | 2018-10-26 | |
US62/751,530 | 2018-10-26 | ||
US201962824539P | 2019-03-27 | 2019-03-27 | |
US62/824,539 | 2019-03-27 | ||
US201962846297P | 2019-05-10 | 2019-05-10 | |
US62/846,297 | 2019-05-10 | ||
PCT/US2019/057569 WO2020086665A1 (en) | 2018-10-26 | 2019-10-23 | Epcam antibodies, activatable antibodies, and immunoconjugates, and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022506072A JP2022506072A (ja) | 2022-01-17 |
JPWO2020086665A5 true JPWO2020086665A5 (ko) | 2022-10-31 |
Family
ID=70331831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021523230A Pending JP2022506072A (ja) | 2018-10-26 | 2019-10-23 | EpCAM抗体、活性化可能抗体、および免疫複合体、ならびにそれらの使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US20210403594A1 (ko) |
EP (1) | EP3873512A4 (ko) |
JP (1) | JP2022506072A (ko) |
KR (1) | KR20210095874A (ko) |
CN (1) | CN113194985A (ko) |
AU (1) | AU2019364400A1 (ko) |
BR (1) | BR112021007918A2 (ko) |
CA (1) | CA3117548A1 (ko) |
IL (1) | IL282496A (ko) |
MX (1) | MX2021004808A (ko) |
SG (1) | SG11202103949SA (ko) |
TW (1) | TW202029980A (ko) |
WO (1) | WO2020086665A1 (ko) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4359438A1 (en) * | 2021-06-21 | 2024-05-01 | Bristol-Myers Squibb Company | Use of sucrose, mannitol and glycine to reduce reconstitution time of high concentration lyophilized biologics drug products |
WO2023183888A1 (en) | 2022-03-23 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable antigen-binding protein constructs and uses of the same |
WO2023183923A1 (en) | 2022-03-25 | 2023-09-28 | Cytomx Therapeutics, Inc. | Activatable dual-anchored masked molecules and methods of use thereof |
WO2023192606A2 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Cd3-binding proteins and methods of use thereof |
WO2023192973A1 (en) | 2022-04-01 | 2023-10-05 | Cytomx Therapeutics, Inc. | Activatable multispecific molecules and methods of use thereof |
WO2024015830A1 (en) | 2022-07-12 | 2024-01-18 | Cytomx Therapeutics, Inc. | Epcam immunoconjugates and uses thereof |
WO2024030845A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030850A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030843A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
WO2024030858A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable substrates and methods of use thereof |
WO2024030847A1 (en) | 2022-08-01 | 2024-02-08 | Cytomx Therapeutics, Inc. | Protease-cleavable moieties and methods of use thereof |
Family Cites Families (48)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
WO1997011971A1 (en) | 1995-09-28 | 1997-04-03 | Alexion Pharmaceuticals, Inc. | Porcine cell interaction proteins |
WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
ATE336514T1 (de) | 2000-02-11 | 2006-09-15 | Merck Patent Gmbh | Steigerung der zirkulierenden halbwertzeit von auf antikörpern basierenden fusionsproteinen |
ES2727425T3 (es) | 2000-12-12 | 2019-10-16 | Medimmune Llc | Moléculas con semividas prolongadas, composiciones y usos de las mismas |
US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
WO2004002431A2 (en) * | 2002-07-01 | 2004-01-08 | Biogen, Inc. | Humanized anti-lymphotoyin beta receptor antibodies |
AU2003259163B2 (en) | 2002-08-16 | 2008-07-03 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
US8367805B2 (en) | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
US7700099B2 (en) | 2005-02-14 | 2010-04-20 | Merck & Co., Inc. | Non-immunostimulatory antibody and compositions containing the same |
US7666817B2 (en) | 2005-08-31 | 2010-02-23 | The Regents Of The University Of California | Cellular libraries of peptide sequences (CLiPS) and methods of using the same |
EP3124029A1 (en) | 2006-03-15 | 2017-02-01 | Alexion Pharmaceuticals, Inc. | Treatment of paroxysmal nocturnal hemoglobinuria patients by an inhibitor of complement |
CN101448853A (zh) * | 2006-03-17 | 2009-06-03 | 比奥根艾迪克Ma公司 | 稳定的多肽组合物 |
SG10201501103RA (en) | 2006-05-30 | 2015-04-29 | Genentech Inc | Antibodies And Immunoconjugates And Uses Therefor |
SI2019104T1 (sl) | 2007-07-19 | 2013-12-31 | Sanofi | Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba |
CA3128656A1 (en) | 2007-08-22 | 2009-02-26 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
KR20210005318A (ko) | 2008-04-30 | 2021-01-13 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
UA108598C2 (xx) | 2008-04-30 | 2015-05-25 | Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери) | |
CA2726845C (en) | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
GB0819095D0 (en) | 2008-10-17 | 2008-11-26 | Spirogen Ltd | Pyrrolobenzodiazepines |
RU2636046C2 (ru) | 2009-01-12 | 2017-11-17 | Сайтомкс Терапьютикс, Инк | Композиции модифицированных антител, способы их получения и применения |
NZ594177A (en) | 2009-02-05 | 2014-02-28 | Immunogen Inc | Novel benzodiazepine derivatives |
KR20110140124A (ko) | 2009-04-08 | 2011-12-30 | 하인즈 파울스티히 | 암치료용 아미톡신-활성 표적 결합 부위 |
GB0909904D0 (en) * | 2009-06-09 | 2009-07-22 | Affitech As | Product |
NZ602933A (en) | 2010-04-15 | 2014-09-26 | Seattle Genetics Inc | Pyrrolobenzodiazepines used to treat proliferative diseases |
SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
WO2013177481A1 (en) | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
US9309510B2 (en) | 2012-08-10 | 2016-04-12 | Cytomx Therapeutics, Inc. | Protease-resistant systems for polypeptide display and methods of making and using thereof |
US9790274B2 (en) * | 2013-03-14 | 2017-10-17 | The Board Of Regents Of The University Of Texas System | Monoclonal antibodies targeting EpCAM for detection of prostate cancer lymph node metastases |
JP6464255B2 (ja) * | 2014-08-04 | 2019-02-06 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性t細胞活性化抗原結合分子 |
JP2017527562A (ja) | 2014-09-03 | 2017-09-21 | イミュノジェン・インコーポレーテッド | 細胞毒性ベンゾジアゼピン誘導体 |
RS60751B1 (sr) | 2014-09-03 | 2020-10-30 | Immunogen Inc | Citotoksični derivati benzodiazepina |
AU2016228755B2 (en) * | 2015-03-12 | 2020-09-10 | Viventia Bio Inc. | Methods of treatment for EPCAM positive bladder cancer |
CA2925329C (en) * | 2015-04-13 | 2024-01-02 | Pfizer Inc. | Anti-bcma antibodies, anti-cd3 antibodies and bi-specific antibodies binding to bcma and cd3 |
JP7028648B2 (ja) | 2015-05-04 | 2022-03-02 | サイトメックス セラピューティクス インコーポレイテッド | 抗cd166抗体、活性化可能抗cd166抗体、およびその使用方法 |
SG11201710734UA (en) * | 2015-06-24 | 2018-01-30 | Japan Chem Res | Anti-human transferrin receptor antibody permeating blood-brain barrier |
RU2733740C2 (ru) | 2015-06-29 | 2020-10-06 | Иммуноджен, Инк. | Конъюгаты сконструированных антител с цистеиновыми заменами |
WO2017023704A1 (en) * | 2015-07-31 | 2017-02-09 | Sutro Biopharma, Inc. | ANTI-EpCAM ANTIBODIES, COMPOSITIONS COMPRISING ANTI-EpCAM ANTIBODIES AND METHODS OF MAKING AND USING ANTI-EpCAM ANTIBODIES |
EP3328894B1 (en) * | 2015-08-06 | 2018-11-14 | Agency For Science, Technology And Research | Il2rbeta/common gamma chain antibodies |
-
2019
- 2019-10-22 TW TW108138004A patent/TW202029980A/zh unknown
- 2019-10-23 EP EP19876033.2A patent/EP3873512A4/en active Pending
- 2019-10-23 WO PCT/US2019/057569 patent/WO2020086665A1/en unknown
- 2019-10-23 MX MX2021004808A patent/MX2021004808A/es unknown
- 2019-10-23 SG SG11202103949SA patent/SG11202103949SA/en unknown
- 2019-10-23 CN CN201980084482.4A patent/CN113194985A/zh active Pending
- 2019-10-23 BR BR112021007918-1A patent/BR112021007918A2/pt unknown
- 2019-10-23 KR KR1020217015710A patent/KR20210095874A/ko active Search and Examination
- 2019-10-23 AU AU2019364400A patent/AU2019364400A1/en active Pending
- 2019-10-23 JP JP2021523230A patent/JP2022506072A/ja active Pending
- 2019-10-23 CA CA3117548A patent/CA3117548A1/en active Pending
- 2019-10-23 US US17/288,469 patent/US20210403594A1/en active Pending
-
2021
- 2021-04-20 IL IL282496A patent/IL282496A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11918656B2 (en) | Antibody-drug-conjugate and its use for the treatment of cancer | |
JP6333882B2 (ja) | 抗体−薬剤コンジュゲート | |
US9828428B2 (en) | Anti-IL-13 receptor alpha 2 antibodies and antibody-drug conjugates | |
JP6817674B2 (ja) | 抗ntb−a抗体ならびに関連する組成物および方法 | |
AU2019272250B2 (en) | Anti-mesothelin antibody and antibody-drug conjugate thereof | |
WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
JP7191134B2 (ja) | Igf-1r抗体および癌処置のためのアドレッシングビヒクルとしてのその使用 | |
US20240033369A1 (en) | Anti-cd228 antibodies and antibody-drug conjugates | |
AU2015250759B2 (en) | IGF-1R antibody-drug-conjugate and its use for the treatment of cancer | |
JP2009522329A (ja) | 線維芽細胞活性化タンパク質に特異的な抗体分子及びそれを含む免疫複合体 | |
JP2022008618A (ja) | Muc1に特異的に結合する抗体及びその用途 | |
US11827709B2 (en) | Anti-AVB6 antibodies and antibody-drug conjugates | |
RU2019129839A (ru) | Производные майтанзиноида с саморасщепляющимися пептидными линкерами и их конъюгаты | |
JPWO2020086665A5 (ko) | ||
IL305954A (en) | Nectin-4 protein antibody and extacan compounds |